549 related articles for article (PubMed ID: 31500315)
1. Immune and Inflammatory Cells in Thyroid Cancer Microenvironment.
Ferrari SM; Fallahi P; Galdiero MR; Ruffilli I; Elia G; Ragusa F; Paparo SR; Patrizio A; Mazzi V; Varricchi G; Marone G; Antonelli A
Int J Mol Sci; 2019 Sep; 20(18):. PubMed ID: 31500315
[TBL] [Abstract][Full Text] [Related]
2. Immune Landscape of Thyroid Cancers: New Insights.
Menicali E; Guzzetti M; Morelli S; Moretti S; Puxeddu E
Front Endocrinol (Lausanne); 2020; 11():637826. PubMed ID: 33986723
[TBL] [Abstract][Full Text] [Related]
3. The Immune Landscape of Thyroid Cancer in the Context of Immune Checkpoint Inhibition.
Varricchi G; Loffredo S; Marone G; Modestino L; Fallahi P; Ferrari SM; de Paulis A; Antonelli A; Galdiero MR
Int J Mol Sci; 2019 Aug; 20(16):. PubMed ID: 31412566
[TBL] [Abstract][Full Text] [Related]
4. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
[TBL] [Abstract][Full Text] [Related]
5. Targeting the immune microenvironment for ovarian cancer therapy.
Blanc-Durand F; Clemence Wei Xian L; Tan DSP
Front Immunol; 2023; 14():1328651. PubMed ID: 38164130
[TBL] [Abstract][Full Text] [Related]
6. Inflammatory Components of the Thyroid Cancer Microenvironment: An Avenue for Identification of Novel Biomarkers.
Jarboe T; Tuli NY; Chakraborty S; Maniyar RR; DeSouza N; Xiu-Min Li ; Moscatello A; Geliebter J; Tiwari RK
Adv Exp Med Biol; 2021; 1350():1-31. PubMed ID: 34888842
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitors as mediators for immunosuppression by cancer-associated fibroblasts: A comprehensive review.
Eskandari-Malayeri F; Rezaei M
Front Immunol; 2022; 13():996145. PubMed ID: 36275750
[TBL] [Abstract][Full Text] [Related]
8. Cell Component and Function of Tumor Microenvironment in Thyroid Cancer.
Shin E; Koo JS
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293435
[TBL] [Abstract][Full Text] [Related]
9. Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy.
Albini A; Bruno A; Noonan DM; Mortara L
Front Immunol; 2018; 9():527. PubMed ID: 29675018
[TBL] [Abstract][Full Text] [Related]
10. Recent advances in understanding immune phenotypes of thyroid carcinomas: prognostication and emerging therapies.
Liotti F; Prevete N; Vecchio G; Melillo RM
F1000Res; 2019; 8():. PubMed ID: 30854191
[TBL] [Abstract][Full Text] [Related]
11. Chemopreventive agents targeting tumor microenvironment.
Sharma SH; Thulasingam S; Nagarajan S
Life Sci; 2016 Jan; 145():74-84. PubMed ID: 26679106
[TBL] [Abstract][Full Text] [Related]
12. Current and future immunotherapies for thyroid cancer.
Antonelli A; Ferrari SM; Fallahi P
Expert Rev Anticancer Ther; 2018 Feb; 18(2):149-159. PubMed ID: 29241377
[TBL] [Abstract][Full Text] [Related]
13. Regulation of tumor infiltrated innate immune cells by adenosine.
Strakhova R; Cadassou O; Cros-Perrial E; Jordheim LP
Purinergic Signal; 2020 Sep; 16(3):289-295. PubMed ID: 32529478
[TBL] [Abstract][Full Text] [Related]
14. The role of the inflammatory microenvironment in thyroid carcinogenesis.
Cunha LL; Marcello MA; Ward LS
Endocr Relat Cancer; 2014 Jun; 21(3):R85-R103. PubMed ID: 24302667
[TBL] [Abstract][Full Text] [Related]
15. Mast cells as effector cells of innate immunity and regulators of adaptive immunity.
Cardamone C; Parente R; Feo GD; Triggiani M
Immunol Lett; 2016 Oct; 178():10-4. PubMed ID: 27393494
[TBL] [Abstract][Full Text] [Related]
16. Tumor microenvironment in thyroid cancer: Immune cells, patterns, and novel treatments.
Febrero B; Ruiz-Manzanera JJ; Ros-Madrid I; Hernández AM; Orenes-Piñero E; Rodríguez JM
Head Neck; 2024 Jun; 46(6):1486-1499. PubMed ID: 38380767
[TBL] [Abstract][Full Text] [Related]
17. Role of mast cells activation in the tumor immune microenvironment and immunotherapy of cancers.
Guo X; Sun M; Yang P; Meng X; Liu R
Eur J Pharmacol; 2023 Dec; 960():176103. PubMed ID: 37852570
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of BRAF Sensitizes Thyroid Carcinoma to Immunotherapy by Enhancing tsMHCII-mediated Immune Recognition.
Zhi J; Zhang P; Zhang W; Ruan X; Tian M; Guo S; Zhang W; Zheng X; Zhao L; Gao M
J Clin Endocrinol Metab; 2021 Jan; 106(1):91-107. PubMed ID: 32936899
[TBL] [Abstract][Full Text] [Related]
19. Tumor Microenvironment and Nitric Oxide: Concepts and Mechanisms.
Vedenko A; Panara K; Goldstein G; Ramasamy R; Arora H
Adv Exp Med Biol; 2020; 1277():143-158. PubMed ID: 33119871
[TBL] [Abstract][Full Text] [Related]
20. Innate immune cells in the tumor microenvironment.
Li MO; Wolf N; Raulet DH; Akkari L; Pittet MJ; Rodriguez PC; Kaplan RN; Munitz A; Zhang Z; Cheng S; Bhardwaj N
Cancer Cell; 2021 Jun; 39(6):725-729. PubMed ID: 34129817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
